CEL-SCI shares Phase 3 Multikine data showing 73% survival rate
Tweet Send to a Friend
CEL-SCI Corporation (NYSE American: CVM) presented new data from its completed Phase 3 study of Multikine (Leukocyte Interleukin, Injection) at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




